{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:21:30Z","timestamp":1769595690767,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s13730-021-00668-w","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T14:02:51Z","timestamp":1637762571000},"page":"265-268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2050-9907","authenticated-orcid":false,"given":"Shinichi","family":"Mizuno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chigusa","family":"Kitayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeto","family":"Mashiko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Sanada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"key":"668_CR1","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","volume":"28","author":"MA Dimopoulos","year":"2010","unstructured":"Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28:4976\u201384.","journal-title":"J Clin Oncol"},{"key":"668_CR2","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/ki.2011.94","volume":"79","author":"K Basnayake","year":"2011","unstructured":"Basnayake K, Stringer SJ, Hutchison CA, Cockwell P. The biology of immunoglobulin free light chains and kidney injury. Kidney Int. 2011;79:1289\u2013301.","journal-title":"Kidney Int"},{"key":"668_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ajh.24335","volume":"91","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Eleutherakis-Papaiakovou E, Migkou M, et al. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol. 2016;91:499\u2013502.","journal-title":"Am J Hematol"},{"key":"668_CR4","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1182\/bloodadvances.2016003905","volume":"1","author":"C Botta","year":"2017","unstructured":"Botta C, Cilibetrto D, Rossi M, Staropoli N, Cuc\u00e8 M, Galeano T, et al. Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed\/refractory patients. Blood Adv. 2017;1:455\u201366.","journal-title":"Blood Adv"},{"key":"668_CR5","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380:2104\u201315.","journal-title":"N Engl J Med"},{"key":"668_CR6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378:518\u201328.","journal-title":"N Engl J Med"},{"key":"668_CR7","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1681\/ASN.2010080857","volume":"22","author":"CA Hutchison","year":"2011","unstructured":"Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol. 2011;22:1129\u201336.","journal-title":"J Am Soc Nephrol"},{"key":"668_CR8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/leu.2012.182","volume":"27","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013;27:423\u20139.","journal-title":"Leukemia"},{"key":"668_CR9","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1200\/JCO.19.00231","volume":"37","author":"RF Cornell","year":"2019","unstructured":"Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol. 2019;37:1946\u201355.","journal-title":"J Clin Oncol"},{"key":"668_CR10","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1080\/10428194.2017.1365859","volume":"59","author":"E Diamond","year":"2018","unstructured":"Diamond E, Lahoud OB, Landau H. Managing multiple myeloma in elderly patients. Leuk Lymphoma. 2018;59:1300\u201311.","journal-title":"Leuk Lymphoma"},{"key":"668_CR11","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s12185-020-02948-0","volume":"112","author":"S Mizuno","year":"2020","unstructured":"Mizuno S, Kitayama C, Yamaguchi K, Sanada S, Sato T. Successful management of hemodialysis-dependent refractory myeloma with modified daratumumab, bortezomib and dexamethasone regimen. Int J Hematol. 2020;112:860\u20133.","journal-title":"Int J Hematol"},{"key":"668_CR12","doi-asserted-by":"publisher","first-page":"e370","DOI":"10.1016\/S2352-3026(20)30070-3","volume":"7","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka P, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomized, phase 3 trial. Lancet Haematol. 2020;7:e370\u201380.","journal-title":"Lancet Haematol"},{"key":"668_CR13","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.3324\/haematol.2018.191122","volume":"103","author":"S Rocchi","year":"2018","unstructured":"Rocchi S, Tacchetti P, Pantani L, Mancuso K, Zannetti B, Cavo M, et al. Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma. Haematologica. 2018;103:e277\u20138.","journal-title":"Haematologica"},{"key":"668_CR14","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s11845-018-1951-6","volume":"188","author":"E Smyth","year":"2019","unstructured":"Smyth E, Glavey S, Melotti D, Thornton P, Sargent J, Conlon P, et al. Dialysis independence following single-agent daratumumab in refractory myeloma with renal failure. Ir J Med Sci. 2019;188:1079\u201380.","journal-title":"Ir J Med Sci"},{"key":"668_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.5045\/br.2020.55.1.65","volume":"55","author":"P Jeyaraman","year":"2020","unstructured":"Jeyaraman P, Bhasin A, Dayal N, Pathak S, Naithani R. Daratumumab in dialysis-dependent multiple myeloma. Blood Res. 2020;55:62\u20137.","journal-title":"Blood Res"},{"key":"668_CR16","doi-asserted-by":"publisher","first-page":"e395","DOI":"10.1016\/j.clml.2020.03.014","volume":"20","author":"DC Moore","year":"2020","unstructured":"Moore DC, Arnall JR, Janes A, Pineda-Roman M. Dialysis independence following combination daratumumab, thalidomide, bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma with severe renal failure. Clin Lymphoma Myeloma Leuk. 2020;20:e395\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"668_CR17","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1111\/bjh.16286","volume":"190","author":"MJ Cejalvo","year":"2020","unstructured":"Cejalvo MJ, Legarda M, Abella E, Cabezudo E, Encinas C, Garc\u00eda-Feria A, et al. Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study. Br J Haematol. 2020;190:e289\u201392.","journal-title":"Br J Haematol"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-021-00668-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-021-00668-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-021-00668-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T13:19:57Z","timestamp":1651497597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-021-00668-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["668"],"URL":"https:\/\/doi.org\/10.1007\/s13730-021-00668-w","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]},"assertion":[{"value":"6 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest associated with this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent was obtained from the patient in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}